These findings suggest that different KRAS mutations may lead to distinct metabolic changes in colorectal cancer cells, with G12V mutations potentially having a greater impact on lipid metabolism due to higher ACSS2 expression levels. The gene discussed is KRAS; the disease is colorectal cancer.